SAN DIEGO, CA / ACCESSWIRE / August 17, 2021 / Dermatologist Therapeutics:, Inc. (“Dermata” or “Company”) (NASDAQ: DRMA, DRMAW), At the clinical stage, the Medical Dermatology Company, which focuses on the discovery and development of candidates for innovative pharmaceutical products for the treatment of dermatological conditions, announced today the closing of its initial public offering of 2,571,428 shares. Each common stock was sold for a share price of $ 7.00 per share, with a combined bid of $ 7.00 per share, for about $ 18.0 million gross earnings, before deducting placement discounts. In addition, Dermata provided policyholders with a 45-day option to acquire up to 5 385,714 additional shares և and / or to acquire a total of 385,714 shares to cover overpayments at the initial public offering price by reducing insurance. Discount, from which “Maxim Group” LLC used its option to buy additional 385,714 guarantees. All Shares of Ordinary Shares: Guarantee offered by the Company.

Shares of common stock securities on the Nasdaq Capital Market started trading on August 13, 2021 under the symbols “DRMA” and “DRMAW”, respectively.

The company intends to use the substantial net profit of the offer to promote the clinical development of DMT310 for the treatment of rosacea և psoriasis, to advance the clinical development of DMT410 for the treatment of various aesthetic indications, to fund its planned non-clinical trials և Pharmacokinetic study for its DMT , for the production of medicinal products for the clinical trials of acne, rosacea, psoriasis, payment to the licensor, working capital, other general corporate purposes.

Maxim Group LLC was the sole book manager, and Brookline Capital Markets, a division of Arcadia Securities LLC, acted as co-administrator of the offer.

The S-1 horse (Case Nos. 333-256997 և 333-258772) was registered with the Securities and Exchange Commission (“SEC”), which entered into force on August 12, 2021. A final proposal proposal has been submitted to the SEC and is available on the SEC website at The offer was made only through a prospectus that is part of an effective registration declaration. Electronic copies of this prospectus can be obtained from Maxim Group LLC at 300 Park Avenue, 16th Floor, New York, New York 10022, (212) 895-3745. Prior to investing in this offer, interested parties should read the full registration statement submitted by the Company to the SEC, which provides additional information about the Company և this offer.

This press release should not be a sale or purchase offer, nor should it be a sale of those securities in any State or jurisdiction in which such offer, request or sale would be unlawful prior to registration or qualification. by the laws of any state or jurisdiction.

About Dermata Therapeutics
Dermata is a clinical dermatology company focused on identifying, developing and commercializing candidates for innovative pharmaceutical products for the treatment of skin medical and aesthetic diseases. For more information, visit

Prospective announcements
This press release contains some forward-looking statements, including other predictive statements about revenue use. Future reports are based on the Company ընթաց’s current expectations: assumptions. 1995 The Law on Reform of Private Securities Disputes provides a secure future for promising announcements. These statements can be identified by the use of prospective expressions, including but not limited to “expect”, “predict”, “intend”, “plan”, “believe”, “evaluate”, “potential”. to predict, “project”, “should”, “there are” such expressions բաց the negative aspects of those terms. Prospective investors are advised not to rely unnecessarily on such future statements, which speak only as of the date of this presentation. The Company has no obligation to publicly update any prospective announcement with new information, future events or otherwise. Important factors that may cause the actual results to differ materially from those of future reports are set out in the Company’s documents submitted to the Securities and Exchange Commission, including its S-1 registration statement, which is amended from time to time under the heading “Risk Factors”. :

Sean Profile
Investor relations
(858) 800-2543 Additional 705

A SO BYOR. Dermata Therapeutics:

See the source version at